Caregiver Outcomes of Alzheimer's Disease Screening
(COADS Trial)

Recruiting in Palo Alto (17 mi)

+1 other location

Overseen byNicole Fowler, PHD

Age: 65+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Indiana University

No Placebo Group

Trial Summary

What is the purpose of this trial?

This study will measure the risks and benefits of early screening of Alzheimer's disease. Early diagnosis through screening may enhance the family member's transition to a family caregiver and reduce caregiver burden by providing an opportunity for the family member to learn about the syndrome, receive interventions, and to prepare for their new care giving role.

Research Team

Nicole Fowler, PHD

Principal Investigator

Indiana University

Eligibility Criteria

Inclusion Criteria

I'm sorry, but "Family Members" is not specific enough to be a screening criterion. Can you please provide more information or context?

You must be at least 21 years old.

You understand the study and agree to participate in it.

See 7 more

Treatment Details

Interventions

Collaborative Dementia Care Program (Behavioral Intervention)
Screening Only (Other)

Participant Groups

3Treatment groups

Experimental Treatment

Active Control

Group I: Collaborative Dementia Care ProgramExperimental Treatment1 Intervention

The patients in this group will receive screening for AD, Patients and family members will receive a letter about how the patient performed on the screening. If they screen positive (e.g. ≤5 on the MIS-T or ≤2 on the Mini-Cog), the patient and family member will receive an infographic. Also, the family member will receive two follow-up phone calls. One from the COADS Study Coordinator and one from a care coordinator at the Aging Brain Care Program (ABC). This phone call will include an opportunity for the family to ask questions and a conversation about the program and diagnostic evaluation and management. Dyads have the option to refuse the follow-up visit. The patient's PCP is also be notified of the screening results via EHR message,

Group II: ControlActive Control1 Intervention

The patients in this group will receive no AD screening

Group III: Screening OnlyActive Control1 Intervention

The patients in this group will receive screening for AD. Patients and family members will receive a letter about how the patient performed on the screening. If they screen positive (e.g. ≤5 on the MIS-T or ≤2 on the Mini-Cog), the patient and family member will receive an infographic and some information about local clinical resources for them to peruse regarding follow-up care. The patient's PCP is also be notified of the screening results via EHR message.